Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up – What’s Next?

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) gapped up before the market opened on Friday . The stock had previously closed at $10.89, but opened at $14.18. Amicus Therapeutics shares last traded at $14.1850, with a volume of 81,627,376 shares changing hands.

Trending Headlines about Amicus Therapeutics

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: BioMarin to acquire Amicus for ~$4.8B ($14.50 per share), citing complementary marketed products (Galafold, Pombiliti + Opfolda), $599M of recent revenue and expectations the deal will be accretive to non‑GAAP EPS within 12 months — this provides a clear exit price and strategic rationale that pushed the stock up. Article Title
• Positive Sentiment: BioMarin’s press release emphasizes revenue upside from bringing Amicus products into BioMarin’s global footprint and resolving pending patent litigation on Galafold — details that support the acquisition valuation and near-term revenue accretion view. Article Title
• Neutral Sentiment: Trading was temporarily halted pre-market for “news pending,” then resumed around the acquisition announcement — a procedural sign the market treated the item as material. (Trading halt noted in market alerts.)
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a “neutral” rating with a $14.50 price target (roughly in line with the deal price), and Needham reiterated a “hold” — analyst stances imply limited upside beyond the announced offer price absent a competing bidder. Article Title
• Negative Sentiment: Two investor‑rights firms (Halper Sadeh LLC and The Ademi Firm) announced investigations into whether the $14.50 per‑share sale is fair to Amicus shareholders — litigation or proxy fights could delay closing, pressure timing, or open the door to a higher bid/renegotiation, increasing deal execution risk. Article Title
• Negative Sentiment: Insider selling disclosures (including recent sales by the CEO and another officer) surfaced in filings earlier this week — while not unusual, these sales add a note of caution for some investors evaluating management alignment ahead of the deal. Article Title

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Needham & Company LLC downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Monday, December 15th. Cantor Fitzgerald lowered shares of Amicus Therapeutics from an “overweight” rating to a “hold” rating and dropped their price target for the company from $21.00 to $14.50 in a research report on Friday. Finally, Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.36.

Amicus Therapeutics Trading Up 30.4%

The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.09 and a current ratio of 2.99. The firm has a 50 day simple moving average of $9.48 and a two-hundred day simple moving average of $7.84. The firm has a market capitalization of $4.38 billion, a P/E ratio of -354.81 and a beta of 0.46.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.12 by $0.05. The company had revenue of $169.06 million during the quarter, compared to the consensus estimate of $165.24 million. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The firm’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.10 earnings per share. Equities research analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Insider Activity at Amicus Therapeutics

In related news, insider David Michael Clark sold 25,643 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $11.00, for a total transaction of $282,073.00. Following the completion of the transaction, the insider owned 271,332 shares in the company, valued at approximately $2,984,652. This represents a 8.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ellen Rosenberg sold 36,000 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $10.00, for a total transaction of $360,000.00. Following the transaction, the insider directly owned 507,710 shares of the company’s stock, valued at $5,077,100. This represents a 6.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 319,808 shares of company stock valued at $3,293,653 over the last quarter. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Allworth Financial LP increased its stake in Amicus Therapeutics by 36.3% in the third quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,246 shares during the last quarter. Allianz Asset Management GmbH increased its stake in shares of Amicus Therapeutics by 0.3% during the third quarter. Allianz Asset Management GmbH now owns 389,109 shares of the biopharmaceutical company’s stock valued at $3,066,000 after buying an additional 1,333 shares during the period. Van ECK Associates Corp lifted its position in shares of Amicus Therapeutics by 35.1% in the 3rd quarter. Van ECK Associates Corp now owns 5,638 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,466 shares during the period. Parallel Advisors LLC raised its stake in Amicus Therapeutics by 40.2% in the third quarter. Parallel Advisors LLC now owns 5,756 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 1,649 shares in the last quarter. Finally, Gotham Asset Management LLC boosted its position in shares of Amicus Therapeutics by 1.5% during the third quarter. Gotham Asset Management LLC now owns 138,523 shares of the biopharmaceutical company’s stock valued at $1,092,000 after purchasing an additional 1,987 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.